MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Price Stock Quantity  
USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MK-2206 2HCl Chemical Structure

MK-2206 2HCl Chemical Structure
Molecular Weight: 480.39

Validation & Quality Control

Product Use Citation(170)

Customer Product Validation(18)

Quality Control & MSDS

Related Compound Libraries

MK-2206 2HCl is available in the following compound libraries:

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Product Information

  • Compare Akt Inhibitors
    Compare Akt Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Targets Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
IC50 8 nM 12 nM 65 nM
In vitro MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H292MVLDfZRwfG:6aXOgRZN{[Xl?NGTzUFY{KM7:TR?=NVy1S2ZIPzJiaB?=NY[3d495TE2VTx?=NFHZPVVKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?=M1n4N|IxPTdzME[5
A431NH\xd4pMcW6jc3WgRZN{[Xl?MY[1JO69VQ>?MnXQOUBpNF\3bIpFVVORMUXTeZBxemW|c3XzJJRp\SC|aXfuZYxqdmdib3[gRYt1KGGwZDDFdos>M{HpSVIxPTdzME[5
HepG2MmnUR5l1d3SxeHnjJGF{e2G7NXvtfINtOTBizszNNXHERVdkOjRiaB?=NUnadHZoTE2VTx?=M3HwVHNmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=>NHjwNWkzOTJyNUmyOS=>
Sk-Hep1NWfNbHJQS3m2b4TvfIlkKEG|c3H5MXmxNEDPxE1?MWSyOEBpMmGxSG1UVw>?MkPEV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnniM1f5S|IyOjB3OUK1
OCUT1 cells harbored PIK3CA (H1047R+/+)NF\GOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLuN{DPxE1?NIPoOYU2KGR?NVXRdoFmTE2VTx?=M1XFcmlEPTB;MD6xOEDPxE1?NG\MSGIzOTJ6OUK2Oy=>
K1 cells harbored PIK3CA (E542K+/+)MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\pRVMh|ryPNEX2RZk2KGR?M3PFTWROW09?M1Hz[GlEPTB;MD61NkDPxE1?M4\Hd|IyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+)MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXyN{DPxE1?NGrtVIc2KGR?MYfEUXNQM3PvWGlEPTB;MD6xPEDPxE1?MlrTNlEzQDl{Nke=
C643 cells harbored HRAS (G13R+/−)NVfXXoc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV:zJO69VQ>?NXrkWHFoPSCmNXrKclViTE2VTx?=M4K0XGlEPTB;MD6yO{DPxE1?MYKyNVI5QTJ4Nx?=
Hth7 cells harbored NRAS (Q61R+/−)M4jEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvVUJY{KM7:TR?=NGfTbnU2KGR?MXPEUXNQMl;YTWM2OD12LkWg{txOMmf1NlEzQDl{Nke=
TPC1 cells harbored RET/PTC1 rearrangementNXXuZXJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXSzJO69VQ>?NWPtboJqPSCmMYnEUXNQMl;tTWM2OD1yLkW5JO69VQ>?Ml76NlEzQDl{Nke=
Hth74MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mny2N{DPxE1?MmLpOUBlNGTz[FFFVVORNG\pPVRKSzVyPUKuNVkh|ryPM1HtXlIyOjh7Mk[3
KAT18M2fHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXuzJO69VQ>?MXu1JIQ>NYrhSXlFTE2VTx?=NGm4[FdKSzVyPUSuOlIh|ryPMoriNlEzQDl{Nke=
SW1736MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDqNVAxKM7:TR?=MlXVOUBlMnnQSG1UVw>?NX\KT5o4UUN3ME20O{42PiEQvF2=M3jVPVIyOjh7Mk[3
WROMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XocVExODBizszNMUO1JIQ>NG[xTZlFVVORM2TzXmlEPTB-MUCwNEDPxE1?MmPINlEzQDl{Nke=
TAD2M3fze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrjRWMyODByIN88US=>MY[1JIQ>NVzyNXJ4TE2VTx?=M17NSmlEPTB-MUCwNEDPxE1?MXeyNVI5QTJ4Nx?=
LN229NHvkbVNCeG:ydH;zbZMhSXO|YYm=NGLjOI0xNjVizszNMkPYOlAhcA>?NFPpNoZFVVORM3PRR2F2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmkNEjKXpYzOjB3N{mxOC=>
T98GNXHLNYgzSXCxcITvd4l{KEG|c3H5NILIWpQxNjVizszNMUi2NEBpMYjEUXNQMV3BeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>?MUmyNlA2PzlzNB?=
HC11NWrOVo9VTnWwY4Tpc44hSXO|YYm=MVqxNEDPxE1?NVPaSnozOjRiaB?=NUDLOHJYTE2VTx?=NHrhW45KdmirYnn0d{DPui2lYYPlbY4h[W6mIFHEVnAhe3mwdHjld4l{MVKyNlQzPjZ{MR?=
MOLT-4MmLOR5l1d3SxeHnjJGF{e2G7MnnFNVAh|ryPMXq0PEBpM2jyb2ROW09?M4r2eWlEPTB;MT635qCK|ryPMW[yNlYyPDJ2Mx?=
CEM-RNFHs[mxEgXSxdH;4bYMhSXO|YYm=NEnmR40yOCEQvF2=MmrzOFghcA>?M{HzWGROW09?NX3rNo8zUUN3ME2zMlPjiIoQvF2=MUGyNlYyPDJ2Mx?=
CEM-SM2HCNGN6fG:2b4jpZ{BCe3OjeR?=NWXBPJZ{OTBizszNNU\a[252PDhiaB?=M2O4eGROW09?NGH5TYVKSzVyPUWuNgKBkc7:TR?=NYjl[lRFOjJ4MUSyOFM>
MOLT-4NVvjS5RjTnWwY4Tpc44hSXO|YYm=M3nheFExKM7:TR?=MXiyOEBpMlvoSG1UVw>?NHfhR3RDdG:la4OgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOnIH;mJJRp\SClZXzsJIN6[2ynM2fzdlIzPjF2MkSz
MOLT-4MXvGeY5kfGmxbjDBd5NigQ>?NHnWdng16oDLzszNNXnIN2RKPCCqNYDCS|JtTE2VTx?=M1zsUWlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFOzRU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>?MkPwNlI3OTR{NEO=
CEM-RNFzMfHZHfW6ldHnvckBCe3OjeR?=NVzTSnZkPOLCid88US=>M3TmUVQhcA>?NVXRZ2F[TE2VTx?=MX;JcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFNFGvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI>Ml7tNlI3OTR{NEO=
CEM-SM4LYUWZ2dmO2aX;uJGF{e2G7MW[05qCK|ryPNUXkb4FEPCCqMUnEUXNQNUe2bpJsUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|VCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{M4q1N|IzPjF2MkSz
HepG2 cellNGXpbVFMcW6jc3WgRZN{[Xl?MX6yNEDPxE1?NHWyeWYzPCCqNELo[2tFVVORMlPpSI94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>?NUfaOmNvOjN5OUezNVk>
HepG2 cellMlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLaU2Y{OCEQvF2=M3HTWVI1KGh?MmrvSG1UVw>?NX;pVIRIUW6qaXLpeJMh[2WubDDndo94fGh?MYiyN|c6PzNzOR?=
HepG2 cellM3jaO2Fxd3C2b4Ppd{BCe3OjeR?=NGnKclEzOCEQvF2=MXuyOEBpNYXaeIFtTE2VTx?=MXXJcoR2[2W|IHPlcIwh[XCxcITvd4l{Mk\oNlM4QTd|MUm=
GEOM1\oPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjZOVAxKG6PMVO3NkBpMoXRSG1UVw>?MkLHTY5pcWKrdIOgZ4VtdCCpcn;3eIg>M37BWFI1PThzMkOx
CNE-1NYTsTIZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjIdnpOOTBizszNNYG4XVgxQTZiaB?=M4PXN2ROW09?M2PYcmlEPTB;Mj65OkDPxE1?NYPUTHNxOjV|M{[5NlU>
CNE-2MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGO0elUyOCEQvF2=MkjkPVYhcA>?M13ZeWROW09?MYrJR|UxRTRwNUOg{txOMl[2NlU{OzZ7MkW=
HONE-1NYjNOI9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkC2NVAh|ryPNIrx[VE6PiCqNIPaTXBFVVORNF7BW3lKSzVyPUOuN|ch|ryPMk[4NlU{OzZ7MkW=
SUNE-1M3zQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn72NVAh|ryPM1zYbFk3KGh?NIHPVItFVVORNUPLU3NCUUN3ME2wMlUzKM7:TR?=MonWNlU{OzZ7MkW=
CNE-2M13xeGZ2dmO2aX;uJGF{e2G7NHezengyOCEQvF2=MkTsOFghcA>?NGK5TYVFVVORNWHNZnU4UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCJMR?=MknzNlU{OzZ7MkW=
HONE-1MYXGeY5kfGmxbjDBd5NigQ>?M1e2dFExKM7:TR?=NWX3UHc3PDhiaB?=M3OwXGROW09?Mn3KTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>?MX[yOVM{Pjl{NR?=
NEC8NYLpWoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vXUmlEPTB;MD6wPVY2OSEQvF2=NXHx[4E6W0GQR1XS
P12-ICHIKAWAM1vvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX31UG91UUN3ME2wMlEyPjJizszNMlzKV2FPT0WU
MDA-MB-175-VIIMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\jdFVRUUN3ME2wMlE{PzN6IN88US=>MVnTRW5ITVJ?
AsPC-1NG[2XIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfK[4V1UUN3ME2wMlIzOTJ{IN88US=>NYPGSJFMW0GQR1XS
T47DNF;0NpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvCR|ZKSzVyPUCuNlgzPSEQvF2=M2fHPHNCVkeHUh?=
HHMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrtTWM2OD1yLkOwNlg{KM7:TR?=MkDEV2FPT0WU
MOLT-16NV7CWXB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTBwM{CzNkDPxE1?M175V3NCVkeHUh?=
ES5NI\H[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTBwM{S0OVUh|ryPNGjQOZVUSU6JRWK=
RS4-11MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPVdllOUUN3ME2wMlM1PjFizszNMlHSV2FPT0WU
KARPAS-45NFK1S3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PUU2lEPTB;MD6zO|MzOSEQvF2=MkXsV2FPT0WU
NCI-H720M1XmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojGTWM2OD1yLkO3Olc6KM7:TR?=Mo\HV2FPT0WU
H9MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3qwWmlEPTB;MD6zPFg5OyEQvF2=NYfBS|g2W0GQR1XS
EFM-19MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnUOWRKSzVyPUCuOFQxOSEQvF2=NF\JXFlUSU6JRWK=
SBC-1MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTBwNESwN|Uh|ryPNYfwNlVtW0GQR1XS
A4-FukMmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjyPFdlUUN3ME2wMlQ3QDZ6IN88US=>NI\vdZBUSU6JRWK=
NCI-H1563Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTBwNEixPFkh|ryPMoXvV2FPT0WU
HCC1419MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDpUJBvUUN3ME2wMlQ5QDl{IN88US=>MlrQV2FPT0WU
H-EMC-SSNFjkNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTBwNEm5N|kh|ryPM1LTbnNCVkeHUh?=
BHT-101MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTKZoc3UUN3ME2wMlUzQTZzIN88US=>NX[2TW5TW0GQR1XS
IGROV-1NIPpWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTBwNUWyOFkh|ryPNEDRNHlUSU6JRWK=
HGC-27MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnmWFVKSzVyPUCuOVY4QDNizszNNYrWbVl7W0GQR1XS
MDA-MB-361NYiyZndkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmr0TWM2OD1yLkW3O|YyKM7:TR?=NX7xdGZ4W0GQR1XS
KE-37NG\6eGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITDVW1KSzVyPUCuOVgzPiEQvF2=NYHQRW1nW0GQR1XS
HCC70MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2O0UGlEPTB;MD61PVgzPyEQvF2=M1LUVHNCVkeHUh?=
LNCaP-Clone-FGCNHSzfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHneldKSzVyPUCuOlExPDhizszNMVPTRW5ITVJ?
HAL-01MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFz3bYdKSzVyPUCuOlIyOyEQvF2=NYPFZW9nW0GQR1XS
HTNGi3OnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwNkOyN|kh|ryPNUPkSJZHW0GQR1XS
MDA-MB-415NV7ndIFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUO0eHhiUUN3ME2wMlY{PjJ4IN88US=>MmPYV2FPT0WU
NOS-1MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TPZ2lEPTB;MD62N|czOyEQvF2=MmW1V2FPT0WU
DU-145MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzhblFjUUN3ME2wMlY1PzR3IN88US=>MnS4V2FPT0WU
OCUB-MM{Huc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTBwN{C5OlYh|ryPNFmw[YRUSU6JRWK=
VA-ES-BJNEnXZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDTbW95UUN3ME2wMlc{ODJ3IN88US=>NE\WcXBUSU6JRWK=
J-RT3-T3-5NGTjNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XzUmlEPTB;MD63OFQxOyEQvF2=M{XpT3NCVkeHUh?=
MOLT-4MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2G1d2lEPTB;MD64NFU5OiEQvF2=MWDTRW5ITVJ?
NB7M{[yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTITWM2OD1yLkiyOFEyKM7:TR?=NHjpSGFUSU6JRWK=
L-363NVLzPVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2r5OGlEPTB;MD64N|Q1OiEQvF2=MVXTRW5ITVJ?
NKM-1NXrrZYNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\DOWJKSzVyPUCuPFYzPTNizszNMnr2V2FPT0WU
HOP-92NFH3bIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHmTWM2OD1yLki3NlI{KM7:TR?=NXTqbJlLW0GQR1XS
OAW-42M1\3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\0TWM2OD1yLki4O|Ih|ryPNEe5cJpUSU6JRWK=
HuO9MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTBwOUK3OVEh|ryPMWLTRW5ITVJ?
MFE-280MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\OTWM2OD1yLkm2OFY2KM7:TR?=NG\SZmRUSU6JRWK=
EM-2NFT1dolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfIfVVKSzVyPUCuPVc6OzlizszNNVrFVWpSW0GQR1XS
NCI-H520NGPiVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37SemlEPTB;MD65PFU6OiEQvF2=NGSzT3NUSU6JRWK=
LB2241-RCCMlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHUOY9KSzVyPUCuPVk4OzRizszNM1vaXHNCVkeHUh?=
SK-NEP-1NIDrelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmq0TWM2OD1zLkG0OFg2KM7:TR?=NUHndGZ6W0GQR1XS
LXF-289MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1z3V2lEPTB;MT6xO|E2PiEQvF2=NV\pbVFxW0GQR1XS
EPLC-272HNXjJTVNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PncmlEPTB;MT6xO|I2PiEQvF2=M2XrcHNCVkeHUh?=
COLO-684M1;ieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nvW2lEPTB;MT6yN|czPSEQvF2=MUfTRW5ITVJ?
ES1NGnoNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTufJRbUUN3ME2xMlI1ODZ3IN88US=>MmLVV2FPT0WU
DOHH-2M1iwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTFwMkiyNFMh|ryPMV\TRW5ITVJ?
CTB-1M4W2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTFwMki5PUDPxE1?NFHh[4FUSU6JRWK=
G-401NUfwWIxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rnWWlEPTB;MT6yPVc6PSEQvF2=M1PsR3NCVkeHUh?=
LoVoNVH2R3RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\r[WtKSzVyPUGuN|I2OzRizszNMYrTRW5ITVJ?
Ramos-2G6-4C10Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTFwM{O3NFEh|ryPM1XObHNCVkeHUh?=
MFM-223NH3sUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXvTWM2OD1zLkO0OFYyKM7:TR?=MVXTRW5ITVJ?
PA-1NHjDZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLnTWM2OD1zLkO1NlY2KM7:TR?=MXnTRW5ITVJ?
697MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXBXHBKSzVyPUGuN|c3OTZizszNNFXFO3dUSU6JRWK=
QIMR-WILMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;ndmlEPTB;MT60PVEyPiEQvF2=NEfNU|NUSU6JRWK=
HOSMlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDSZ5hKSzVyPUGuOFk2PThizszNNIn4fXBUSU6JRWK=
DMS-273Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Due2lEPTB;MT61NVk2QSEQvF2=NXvRb|FpW0GQR1XS
ME-180M2nNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TjeWlEPTB;MT61Olg6OSEQvF2=M3PFXHNCVkeHUh?=
HCC2218MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnSTWM2OD1zLk[4NlI2KM7:TR?=NVXQc4R6W0GQR1XS
CAL-54M2DvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTFwN{GyOFIh|ryPNXjyN|hPW0GQR1XS
OMC-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlO1TWM2OD1zLke0Olc4KM7:TR?=M1\TUXNCVkeHUh?=
COR-L105MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIroWm5KSzVyPUGuO|k4OzdizszNMV;TRW5ITVJ?
BV-173NFfINlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3W5PWlEPTB;MT64NVA4PCEQvF2=NWKwTGtLW0GQR1XS
RKONFTJT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXu3XohpUUN3ME2xMlg4OTBzIN88US=>M3;QdHNCVkeHUh?=
SNU-387NXfUNIl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHv1OY5KSzVyPUGuPFg1ODZizszNNVXBR3pnW0GQR1XS
SW1088M4r4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTFwOUS2NFYh|ryPMmD3V2FPT0WU
Hs-578-TMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTJwMUG0N|Mh|ryPNI\zfZdUSU6JRWK=
OC-314Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzpTWM2OD1{LkG1NFg3KM7:TR?=NY[2b2F2W0GQR1XS
RMG-INGrXOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljvTWM2OD1{LkG2N|k5KM7:TR?=MVLTRW5ITVJ?
NCI-H1395M{TCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPhTWM2OD1{LkG4NFkyKM7:TR?=NXPNPWVTW0GQR1XS
GAMGNEXhcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfjO4VrUUN3ME2yMlI{QDR3IN88US=>MYLTRW5ITVJ?
LB1047-RCCM2K4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWm1WZVrUUN3ME2yMlI1OzF5IN88US=>Mn35V2FPT0WU
MN-60MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnz4TWM2OD1{LkK5PVI{KM7:TR?=Ml3WV2FPT0WU
OAW-28NIPxcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;SVoNKSzVyPUKuNlk6PTFizszNMorkV2FPT0WU
NCI-H2228NX6zWplMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYGzS2o1UUN3ME2yMlMyPTV{IN88US=>MYDTRW5ITVJ?
ABC-1NVjzTmR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\RTWM2OD1{LkOzNlU{KM7:TR?=NVK0ZnlGW0GQR1XS
LS-513MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoWzTWM2OD1{LkOzOFg1KM7:TR?=M4rBTnNCVkeHUh?=
KS-1NVfM[HVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjJNHRRUUN3ME2yMlM5OTlzIN88US=>MXPTRW5ITVJ?
NB69MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvXTWM2OD1{LkO4PVg{KM7:TR?=MlTVV2FPT0WU
VM-CUB-1MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nxSmlEPTB;Mj6zPVA5OyEQvF2=MVjTRW5ITVJ?
D-423MGM3nwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjBZoVKSzVyPUKuOFExPDRizszNNV3WNmgzW0GQR1XS
EW-18MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzpbplKSzVyPUKuOFE6OzlizszNMW\TRW5ITVJ?
YH-13Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfG[INKSzVyPUKuOFYyPTNizszNM1;DTHNCVkeHUh?=
T-24M1uybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nlSWlEPTB;Mj60O|g5OSEQvF2=NEfDbo1USU6JRWK=
ES8NH;iRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DocmlEPTB;Mj60PVI5PyEQvF2=M{DPVnNCVkeHUh?=
ES3NF[4SWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfvWFlKSzVyPUKuOFk4PTlizszNMkTFV2FPT0WU
RXF393NWq2[|FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVP3R4ljUUN3ME2yMlYxPDh5IN88US=>M4fSVnNCVkeHUh?=
RPMI-8226NELMfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPOTpM5UUN3ME2yMlYzQTV|IN88US=>NYPVcpFUW0GQR1XS
AGSM1nrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4n3UGlEPTB;Mj63NlE{PyEQvF2=Ml;GV2FPT0WU
HCC1395M2C0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7vN4hKSzVyPUKuO|UyQDdizszNNXPDR2o{W0GQR1XS
MV-4-11NFy5cVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTJwN{WyOlYh|ryPM2\oSnNCVkeHUh?=
A204MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVOwdplUUUN3ME2yMlg{QDd{IN88US=>NVP0VolNW0GQR1XS
MCF7MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml[2TWM2OD1{Lki2NVE4KM7:TR?=M17yS3NCVkeHUh?=
SNU-423NY\JUIk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnBbJp5UUN3ME2yMlg6OjR{IN88US=>MUfTRW5ITVJ?
NCI-H1048MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHJVY9KSzVyPUKuPVY5PjVizszNM3nBNXNCVkeHUh?=
GR-STNVjMd4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTNwMES2NVEh|ryPMUfTRW5ITVJ?
EoL-1-M4XtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4f4Z2lEPTB;Mz6wO|A2QCEQvF2=MkDtV2FPT0WU
HuH-7M2Pv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXvdpBmUUN3ME2zMlA6PDZ2IN88US=>MV7TRW5ITVJ?
OS-RC-2NInsdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LnSWlEPTB;Mz6xNVE6KM7:TR?=NGX2TlNUSU6JRWK=
EW-3MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\wTWM2OD1|LkG5OVI6KM7:TR?=M3THeHNCVkeHUh?=
NCI-H747M4CwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLUN5c{UUN3ME2zMlIxPjl2IN88US=>MmPDV2FPT0WU
EW-16NHLsWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jn[GlEPTB;Mz6yNVg4QSEQvF2=MnnuV2FPT0WU
DOKNWHGVHVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXqNHZKSzVyPUOuNlI5PTlizszNM4HNd3NCVkeHUh?=
HCC2157MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3WXJVxUUN3ME2zMlM5OTd7IN88US=>NXfmfmZzW0GQR1XS
OVCAR-3NFPmU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjDboJKSzVyPUOuOFA4QDZizszNNWq3Spg2W0GQR1XS
NCI-H1623NHS4PW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjLNm1KSzVyPUOuOFEzOjRizszNMULTRW5ITVJ?
H4Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XPOWlEPTB;Mz60OVYzPiEQvF2=MW\TRW5ITVJ?
SW1710MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYT5UW9SUUN3ME2zMlQ3Pjd6IN88US=>NInjeZFUSU6JRWK=
RT-112NF74O3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7XTWM2OD1|LkWyN|g5KM7:TR?=NIDBSXhUSU6JRWK=
DMS-114M1W1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\YeWlEPTB;Mz62NlI4QCEQvF2=M3LNZnNCVkeHUh?=
AN3-CAM3\5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnudYdzUUN3ME2zMlYzPDV4IN88US=>NX61bmp2W0GQR1XS
KNS-62M{G4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HjWWlEPTB;Mz62N|M{QCEQvF2=MX;TRW5ITVJ?
SJRH30NFHZ[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHUOpNKSzVyPUOuOlkyOjJizszNNXGzVWhXW0GQR1XS
G-402NHHqN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrFd5NKSzVyPUOuO|A4OTFizszNMVrTRW5ITVJ?
MHH-PREB-1NULGcXp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;NOnlKSzVyPUOuO|IxOzhizszNMULTRW5ITVJ?
P30-OHKMofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTNwOEC5O|Yh|ryPNIfMR5VUSU6JRWK=
RVH-421MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTNwOEG3PFgh|ryPM2fHfnNCVkeHUh?=
LU-134-ANF;hc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTNwOEi0Nlgh|ryPMVvTRW5ITVJ?
ECC10NYfVfpNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfqTWM2OD1|LkmzOlIzKM7:TR?=MWPTRW5ITVJ?
TGWNVXzenV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{flbWlEPTB;ND6wNlMxPSEQvF2=M{jEb3NCVkeHUh?=
MLMANFz6T49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTRwMEK5OlYh|ryPNVHh[Yx5W0GQR1XS
SCC-25Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH[4TJhKSzVyPUSuNFY2PjZizszNNYDET|ByW0GQR1XS
TYK-nuNWrpU5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjDTWM2OD12LkC5OVM1KM7:TR?=M3fu[nNCVkeHUh?=
LAMA-84M{f3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPKe3BKSzVyPUSuNVQyQTFizszNNFvYN3BUSU6JRWK=
Calu-3NHXYNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjSTWM2OD12LkK0OFE3KM7:TR?=MVjTRW5ITVJ?
NCI-H460NIL3W|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HlTWlEPTB;ND6yOlQ1OyEQvF2=MXPTRW5ITVJ?
EGI-1NE\BNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELRenlKSzVyPUSuN|c4PzhizszNMWPTRW5ITVJ?
NCI-H292Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TWeGlEPTB;ND6zPFE1PiEQvF2=Mnz4V2FPT0WU
HCE-TNHL0OG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDW[|l5UUN3ME20MlQyPTd7IN88US=>M1nwNnNCVkeHUh?=
EW-11NH3wWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\pU|dKSzVyPUSuOFE5OzhizszNMYfTRW5ITVJ?
ATN-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYGxd2w6UUN3ME20MlQ1OzB2IN88US=>NGrEdnpUSU6JRWK=
NB5M1r5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLoTVNKSzVyPUSuOVM3QTdizszNMYjTRW5ITVJ?
KLEM2rJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTRwN{CxPVgh|ryPM4PhXXNCVkeHUh?=
CAL-39MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HtfWlEPTB;ND63NlE1PiEQvF2=M16xcHNCVkeHUh?=
TI-73NUSyT2F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDKTWM2OD12LkiwOlA6KM7:TR?=NEjmOXVUSU6JRWK=
HO-1-N-1NVr0SopDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXewOnlYUUN3ME20Mlk1OiEQvF2=NED3[VJUSU6JRWK=
786-0NYD5XmVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7PTWM2OD12Lkm0Olc{KM7:TR?=NUfWfIo5W0GQR1XS
SK-N-DZMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTRwOU[xOFIh|ryPMlTIV2FPT0WU
NCI-H446NFLENnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXn6bWFLUUN3ME21MlIxODB7IN88US=>NXniSnY3W0GQR1XS
ETK-1NGrW[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2j1fmlEPTB;NT6yNVE3PSEQvF2=NH3qRWRUSU6JRWK=
BT-20Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTVwMkGzOVMh|ryPNGniUYZUSU6JRWK=
MEL-HONX7aTW1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXH3VItZUUN3ME21MlM4OzN4IN88US=>M1TafHNCVkeHUh?=
CAL-27NYn0bFRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rRfGlEPTB;NT60OlM{QSEQvF2=NFjpNplUSU6JRWK=
SW872NX;Fd|hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;KSWlEPTB;NT61PVQzQCEQvF2=MVHTRW5ITVJ?
RPMI-2650NWf4b3dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTVwNk[xPVkh|ryPMkf4V2FPT0WU
PFSK-1Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTVwN{K3N|Ih|ryPMVPTRW5ITVJ?
SF295MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Hj[GlEPTB;NT64NFY{OyEQvF2=NVn0TJdbW0GQR1XS
BeckerMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXnU4FKSzVyPUWuPFY1PzJizszNNGTjPVJUSU6JRWK=
Saos-2M3L4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTVwOE[1N{DPxE1?Mmq5V2FPT0WU
SK-OV-3NES2VW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvifXpvUUN3ME21Mlk6QDF4IN88US=>MY\TRW5ITVJ?
VMRC-RCZMoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTZwMEi3O|Mh|ryPMn;qV2FPT0WU
EW-22Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXDeYtKSzVyPU[uNVk3PDlizszNNVW2[ZlLW0GQR1XS
BT-474NYTaNXdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7ZTWM2OD14LkKzN{DPxE1?NUnjZVl3W0GQR1XS
BFTC-909M2r5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULUSYlEUUN3ME22MlMxOzR3IN88US=>MWDTRW5ITVJ?
NB12NEPEdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPnTZhDUUN3ME22MlM6ODdzIN88US=>MWfTRW5ITVJ?
D-263MGM1Kzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XkZ2lEPTB;Nj60OVE3QSEQvF2=M2W1[nNCVkeHUh?=
SNB75M2Trcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\QWGlEPTB;Nj62NFE1OyEQvF2=Ml3aV2FPT0WU
A704M33MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHWTWM2OD14Lk[zNFYh|ryPMXPTRW5ITVJ?
NCI-H1693M3nIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTZwNkO2NFQh|ryPMXrTRW5ITVJ?
LN-405MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTZwN{m2O|Ih|ryPNFe5N3NUSU6JRWK=
CHL-1M1Pkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXTTWM2OD14LkiwNFc6KM7:TR?=M{X6bHNCVkeHUh?=
A498NFnVWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPWU3RpUUN3ME22MlgyQTZzIN88US=>Mm\EV2FPT0WU
TE-12Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jvUmlEPTB;Nj64N|gyPyEQvF2=MlqzV2FPT0WU
TE-6NELtTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTZwOUOwN|gh|ryPNEDYfFNUSU6JRWK=
AU565NUPYenB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX35N|d{UUN3ME22Mlk3QTV5IN88US=>NVrmdlBIW0GQR1XS
RDNVXLfoNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTZwOUiyPFQh|ryPNXjpSWVXW0GQR1XS
SW1463MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULBeVE{UUN3ME23MlEyOTZ6IN88US=>MX7TRW5ITVJ?
LU-99AMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTdwMUSzNlIh|ryPMnW2V2FPT0WU
NCI-H28NETNOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4S3fGlEPTB;Nz6yPVI1KM7:TR?=NHnJeJdUSU6JRWK=
MC-IXCMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnLdJBKSzVyPUeuOFg2PzZizszNMWHTRW5ITVJ?
GP5dMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTZXpB{UUN3ME23MlQ5PzZ2IN88US=>NWnqUJc4W0GQR1XS
GB-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfrR4g{UUN3ME23MlU1QDB2IN88US=>NWfsVHNnW0GQR1XS
CAL-33NHHJUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTdwNk[yN|Mh|ryPNHnwUXNUSU6JRWK=
MSTO-211HM3WwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXHTWM2OD15Lk[3N|M3KM7:TR?=MoHVV2FPT0WU
TE-5M1;l[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTdwN{mzN|Qh|ryPNFS1[oxUSU6JRWK=
D-566MGNFTSUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fUfWlEPTB;OD6wOFQzQSEQvF2=NG\LcHRUSU6JRWK=
JVM-3MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;Sc2lEPTB;OD6xOVI3QCEQvF2=MUTTRW5ITVJ?
T98GMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRThwMUiwOlch|ryPNX3JdplXW0GQR1XS
HCC1954MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRThwNEWxNFQh|ryPM2DlUXNCVkeHUh?=
SF126MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mni2TWM2OD16LkS1PVM3KM7:TR?=MnPSV2FPT0WU
LB996-RCCM4SxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2P0cmlEPTB;OD61N|I2PyEQvF2=MoO2V2FPT0WU
SKG-IIIaNH\CNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFmw[4ZKSzVyPUiuOlMxPjlizszNNFPIWJBUSU6JRWK=
NCI-SNU-1NXfFSZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFH5XXpKSzVyPUiuOlQ3PDNizszNM3[wcHNCVkeHUh?=
LB771-HNCM1HQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGX6U|FKSzVyPUiuOlQ3QTZizszNNUDOUWpkW0GQR1XS
SCC-4NHXENVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRThwNkiyNVkh|ryPMnTwV2FPT0WU
CAMA-1NX7NO2VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUn3[FdDUUN3ME24Mlc4OTR4IN88US=>NWnIW3lOW0GQR1XS
D-502MGNY\kfXFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvDVo5KSzVyPUiuO|g3OjlizszNM2PRfHNCVkeHUh?=
ESS-1MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLUTWM2OD16Lki4O|A1KM7:TR?=MX3TRW5ITVJ?
HEC-1NFPSbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLMNlNCUUN3ME24Mlg6QDZ4IN88US=>MnvWV2FPT0WU
NB10NEDpWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PLVGlEPTB;OT6wNlIzPCEQvF2=M2K3THNCVkeHUh?=
8505CMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnwTWM2OD17LkC0NlMzKM7:TR?=MXjTRW5ITVJ?
EFO-27NI\Yc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HKemlEPTB;OT6xOlQyOiEQvF2=MlrzV2FPT0WU
HNM{OyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rnPWlEPTB;OT6xOlYzQCEQvF2=M2TI[XNCVkeHUh?=
DSH1MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWq0doZvUUN3ME25MlIxQDdizszNM2XXdHNCVkeHUh?=
NBsusSRNUHY[5ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3Pad2lEPTB;OT6yO|QxOiEQvF2=NEDWXFVUSU6JRWK=
LS-123MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fwWmlEPTB;OT6zNVc3OSEQvF2=NUnTUmVUW0GQR1XS
SHP-77MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\iTWM2OD17LkO5PVM2KM7:TR?=NILOWpBUSU6JRWK=
ACNMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzGTWM2OD17LkWzNlc4KM7:TR?=NF70SIxUSU6JRWK=
U251MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoewTWM2OD17Lk[1OVQ1KM7:TR?=MX3TRW5ITVJ?
A431NH[zSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnTN2lKSzVyPUmuPFAzOzhizszNNWH6bXhvW0GQR1XS
5637MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XKdGlEPTB;OT64OFk5PCEQvF2=NXGwWGF[W0GQR1XS
MDA-MB-157MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjwTWM2OD17LkmyPFc5KM7:TR?=Mm\RV2FPT0WU
A101DMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnXW3hKSzVyPUmuPVk6PzRizszNMVLTRW5ITVJ?
YKG-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7NTWM2OD1zMD6yNFA3KM7:TR?=M2fONHNCVkeHUh?=
LAN-6NHfse|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2r2eGlEPTB;MUCuNlE3PCEQvF2=NHHPeGxUSU6JRWK=
OVCAR-5Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2f1ZmlEPTB;MUCuNlQ{OyEQvF2=MmnXV2FPT0WU
A549NGrzVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLZS|RKSzVyPUGwMlM6PzNizszNM1n6dHNCVkeHUh?=
no-11MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TGb2lEPTB;MUCuOFM2OyEQvF2=NGfDTodUSU6JRWK=
SF539MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHPTWM2OD1zMD65NFQyKM7:TR?=NEXlS2hUSU6JRWK=
A388NF;IWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXv4RohPUUN3ME2xNU4{QDl5IN88US=>Ml7MV2FPT0WU
DELNHP4eo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmmxTWM2OD1zMT60NlQh|ryPNYDIT2F5W0GQR1XS
SW954MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTFzLkS2Olgh|ryPMofCV2FPT0WU
TK10NF3hdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkK4TWM2OD1zMT61NlcyKM7:TR?=MX7TRW5ITVJ?
SW756NHn4XYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPTTWM2OD1zMT61Nlk1KM7:TR?=M{TxUHNCVkeHUh?=
PC-3M1Hxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoD0TWM2OD1zMT61O|Y1KM7:TR?=MoDVV2FPT0WU
ONS-76NFHxT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vJb2lEPTB;MUGuOlM3KM7:TR?=Ml\WV2FPT0WU
A427MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XP[GlEPTB;MUGuO|A6OyEQvF2=NHjqc2hUSU6JRWK=
MEG-01NICzNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;vTWM2OD1zMT63OVA6KM7:TR?=NXvBN|c1W0GQR1XS
BB30-HNCNEP3V3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HafGlEPTB;MUGuO|k5OiEQvF2=M37wdHNCVkeHUh?=
NCI-H1299M4P4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorCTWM2OD1zMT64NFk{KM7:TR?=MWjTRW5ITVJ?
GCTNFPkU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHlSohKSzVyPUGxMlgzOjhizszNM1rCTHNCVkeHUh?=
D-247MGNEnSNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlm2TWM2OD1zMT65OlY{KM7:TR?=Mo\hV2FPT0WU
CFPAC-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fMRmlEPTB;MUGuPVc5OiEQvF2=MnzjV2FPT0WU
EKVXNF3qb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHPcYxGUUN3ME2xNk4xOzF|IN88US=>MYfTRW5ITVJ?
CAL-51MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLIT4xHUUN3ME2xNk4xPzF4IN88US=>Mn3iV2FPT0WU
BB49-HNCMoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TtbWlEPTB;MUKuNVE4PyEQvF2=M1rPZnNCVkeHUh?=
RPMI-7951M2fUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4i0[WlEPTB;MUKuNVg2PCEQvF2=NELrdYJUSU6JRWK=
RH-1M{W3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrrTWM2OD1zMj6yNVg1KM7:TR?=M{\iUXNCVkeHUh?=
BCPAPMlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zzW2lEPTB;MUKuOFc1QSEQvF2=M3HFcXNCVkeHUh?=
GCIYNV3MdldqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTYNIZHUUN3ME2xNk42OjB7IN88US=>MoXMV2FPT0WU
KNS-81-FDM1GwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;zNmlEPTB;MUKuOVg3QSEQvF2=MV;TRW5ITVJ?
KYSE-140MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTF{Lki1PVUh|ryPMoPXV2FPT0WU
Ca-SkiNHe1cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTF{LkmwOFEh|ryPNWO1WIt[W0GQR1XS
TGBC1TKBNFzCZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M12zbmlEPTB;MUKuPVEyPSEQvF2=NXTRbYw4W0GQR1XS
HCC1187MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVrxXHZZUUN3ME2xN{4yQTF{IN88US=>NH76RXlUSU6JRWK=
SJSA-1NI[4OYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fPOWlEPTB;MUOuNlMzPyEQvF2=NV\TSG9UW0GQR1XS
CTV-1M2PIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfo[o17UUN3ME2xN{4{PDVizszNMVTTRW5ITVJ?
WM-115NWrvd4plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFG0NpFKSzVyPUGzMlY1QDNizszNNXu4UnFuW0GQR1XS
CHP-212MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nLOmlEPTB;MUOuPVc{QSEQvF2=NInTS4dUSU6JRWK=
SCC-15MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHKT4tqUUN3ME2xN{46Pzd3IN88US=>NYfTcHM{W0GQR1XS
BPH-1NF;WR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvaWZZKSzVyPUG0MlE3PjRizszNM3PrUnNCVkeHUh?=
SW780Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTF2LkWwNlUh|ryPNXnRVZpFW0GQR1XS
NCI-H2291NGTP[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTrR4FKSzVyPUG0MlU5PzhizszNNVrCe2pjW0GQR1XS
JEG-3M{TZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzvb3RKSzVyPUG0MlY{OjZizszNMYnTRW5ITVJ?
CAL-120MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnv4TWM2OD1zND63NFI4KM7:TR?=MULTRW5ITVJ?
NCI-H23M1\kRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnnOHBKSzVyPUG0Mlc6QTdizszNMnnQV2FPT0WU
MS-1NWnMdWQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13nVWlEPTB;MUSuPVYyOSEQvF2=NHXBfW9USU6JRWK=
PC-14M1vBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXy3VHkxUUN3ME2xOE46PjV2IN88US=>Ml\WV2FPT0WU
D-283MEDNYLLO|luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLuTWM2OD1zNT6wNVEyKM7:TR?=NXTiXGw{W0GQR1XS
OE19M{\hR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHuTXZKSzVyPUG1MlE2PDFizszNNWPU[pdJW0GQR1XS
CAS-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXXOIRKSzVyPUG1MlQyQDRizszNNXHnfphVW0GQR1XS
NCI-H727MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTF3LkSyNlEh|ryPNH\DN2pUSU6JRWK=
SiHaMojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV:5bIM3UUN3ME2xOU44PTl2IN88US=>NFnRN3dUSU6JRWK=
BFTC-905NGPOe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLXTWM2OD1zNT63Olk1KM7:TR?=MliwV2FPT0WU
MDA-MB-453M4\o[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrmfYN[UUN3ME2xOk4yPjR{IN88US=>MXPTRW5ITVJ?
HuP-T3NF7jdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXwcoxCUUN3ME2xOk43Ozd|IN88US=>NWfhNW03W0GQR1XS
SK-LU-1NIq0XnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mor0TWM2OD1zNj62PVU3KM7:TR?=M3;tOHNCVkeHUh?=
Detroit562M4DHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTF4LkezNVgh|ryPNYfmV|EzW0GQR1XS
HCC1569M1[xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmK5TWM2OD1zNj64N|M4KM7:TR?=NF:wcFVUSU6JRWK=
SK-MES-1NHnkbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3rTWM2OD1zNj64OFE6KM7:TR?=NFPJUWFUSU6JRWK=
BB65-RCCNFPzZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfHTWM2OD1zNz6wOFc6KM7:TR?=NUXibW9sW0GQR1XS
LOXIMVIMlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HFc2lEPTB;MUeuNFcxPyEQvF2=MkfWV2FPT0WU
SW1783MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TtTmlEPTB;MUeuNVI5KM7:TR?=M4jNVHNCVkeHUh?=
NH-12NF;rVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\ZPY9KSzVyPUG3MlM{ODNizszNNVHkXXRYW0GQR1XS
UACC-257MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIT3cG1KSzVyPUG3MlU2OTJizszNNHvnZWhUSU6JRWK=
KOSC-2NIXyVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LMSmlEPTB;MUeuOlc2PyEQvF2=MYXTRW5ITVJ?
KG-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTF5Lk[5N|ch|ryPNYjYXZNvW0GQR1XS
M059JMmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPhUHJKSzVyPUG3MlcxOyEQvF2=M122W3NCVkeHUh?=
MHH-NB-11Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\PTWM2OD1zNz65Olc{KM7:TR?=NFfOdJZUSU6JRWK=
EW-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPyTWM2OD1zOD6xN|gzKM7:TR?=MlPOV2FPT0WU
CAL-85-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHoNG9KSzVyPUG4MlI{PTdizszNMkfYV2FPT0WU
639-VNFz5e|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4n4c2lEPTB;MUiuN|M2PCEQvF2=MX\TRW5ITVJ?
C32NVzIeXdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzzTWM2OD1zOD60O|I4KM7:TR?=NWTm[4h[W0GQR1XS
KM-H2NUCw[lVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjnTWM2OD1zOD61NlMzKM7:TR?=MX7TRW5ITVJ?
A253MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTF6LkeyPFYh|ryPMk\kV2FPT0WU
NCI-N87M1LaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLzXW5yUUN3ME2xPE46ODB6IN88US=>NUXIN4Z5W0GQR1XS
8-MG-BAMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zSXWlEPTB;MUmuNFY1PiEQvF2=MUTTRW5ITVJ?
GI-ME-NM1HGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHFTWM2OD1zOT6xOVQ3KM7:TR?=NEnLblNUSU6JRWK=
8305CNW\ERo1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTF7LkKyPFYh|ryPM3flV3NCVkeHUh?=
TE-8NVjLXJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUm0e3dsUUN3ME2xPU4{ODJ2IN88US=>NHHHcW5USU6JRWK=
KYSE-270NXv1VW94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInqT2NKSzVyPUKwMlAzOTdizszNM1PxXnNCVkeHUh?=
HL-60NXGyTXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEf5b2dKSzVyPUKwMlA6PDFizszNMYTTRW5ITVJ?
Mo-TNYHYcZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJyLkG2OlUh|ryPMnHNV2FPT0WU
NCI-H1355NYnK[ZZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13WPGlEPTB;MkCuN|M4PCEQvF2=NFq1ZolUSU6JRWK=
HT-1080MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPxWFBxUUN3ME2yNE42PDl5IN88US=>Mo\tV2FPT0WU
MIA-PaCa-2M1L2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTJyLk[4PFMh|ryPNVrxPIhwW0GQR1XS
NCI-H441NX7rPWNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TEfmlEPTB;MkCuO|M4QSEQvF2=NX24d5J1W0GQR1XS
LCLC-97TM1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\OPFZKSzVyPUKwMlgyOzRizszNNIXUZ4JUSU6JRWK=
HT-3MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfOWWJOUUN3ME2yNU42PjNzIN88US=>MmnpV2FPT0WU
22RV1NGXPWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTJzLkW2PFUh|ryPNXTqS3F4W0GQR1XS
LK-2NXfoW3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPhNHRKSzVyPUKxMlU6PTNizszNNVPicZFVW0GQR1XS
CW-2NIrzTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXS4dZV5UUN3ME2yNU43ODZ7IN88US=>MWrTRW5ITVJ?
KYSE-510M{LOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnNUGNqUUN3ME2yNU43ODl3IN88US=>M37qO3NCVkeHUh?=
CGTH-W-1NYfZfVB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlmwTWM2OD1{MT63NVY3KM7:TR?=M1\SXXNCVkeHUh?=
NCI-H661MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TKUWlEPTB;MkKuNFM1KM7:TR?=M1j0cnNCVkeHUh?=
KU-19-19NH6ycndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vYVGlEPTB;MkKuNVY6PyEQvF2=MVPTRW5ITVJ?
NCI-H2122M{\JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTJ{LkK0N|Ih|ryPMUXTRW5ITVJ?
NCI-H526M17nWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUThW41[UUN3ME2yNk4{QDl3IN88US=>NYriN5lDW0GQR1XS
NCI-H1650NH7iRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPVTWM2OD1{Mj63OlQh|ryPNHXRRXRUSU6JRWK=
AM-38NESwTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmG2TWM2OD1{Mj64Olg6KM7:TR?=NGXRXlBUSU6JRWK=
NCI-H2405NVG4UnZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M124TWlEPTB;MkOuNlU{OyEQvF2=Mki2V2FPT0WU
M14M4TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jQNWlEPTB;MkOuOFA5QCEQvF2=Mn7PV2FPT0WU
ES4NWXPN2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfaWolKSzVyPUKzMlQzOzJizszNM2fhT3NCVkeHUh?=
DJM-1NHXKR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{G1NGlEPTB;MkOuOVI{PCEQvF2=NH7wTI9USU6JRWK=
S-117M3TkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTJ|Lke2OVEh|ryPMXnTRW5ITVJ?
MZ2-MELNHe5R|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTJ|Lke3OVkh|ryPMVzTRW5ITVJ?
SK-MEL-2MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmW2TWM2OD1{Mz64NVM{KM7:TR?=NGHXempUSU6JRWK=
HCC1806NEXYdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M360eGlEPTB;MkOuPFcxQSEQvF2=M1nONnNCVkeHUh?=
NMC-G1NEjaR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJ2LkKyNlYh|ryPMWHTRW5ITVJ?
DK-MGM3nnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInqdJhKSzVyPUK0MlI6PCEQvF2=MVnTRW5ITVJ?
SK-N-FIM{[xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HKVWlEPTB;MkSuN|MxOiEQvF2=NXq5TJJKW0GQR1XS
KINGS-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIriNHRKSzVyPUK0MlQ5PzRizszNNYjEVHZ7W0GQR1XS
HCC2998M4TCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4ezOGlEPTB;MkSuOFg5PSEQvF2=MoraV2FPT0WU
ALL-POMmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf0Z5p[UUN3ME2yOE43OTlizszNNULrXopmW0GQR1XS
MPP-89NX3jepNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{ntZ2lEPTB;MkWuNFQ2QCEQvF2=M4rWeXNCVkeHUh?=
NCI-H2342Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nZfGlEPTB;MkWuNVk2OyEQvF2=NUi4elNLW0GQR1XS
TE-1NWrxeopMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1T5cWlEPTB;MkWuN|U3OyEQvF2=Mm\IV2FPT0WU
RH-18NEL3TVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nHS2lEPTB;MkWuOVkyQCEQvF2=MkP0V2FPT0WU
HT-1376M3Lp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTvTHhQUUN3ME2yOU43PDZ3IN88US=>M37iXHNCVkeHUh?=
U-2-OSMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTJ3Lk[4PFgh|ryPMYnTRW5ITVJ?
BT-549MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTJ3LkmwNVEh|ryPMVHTRW5ITVJ?
NCI-H1755MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7jTWM2OD1{NT65PVQ2KM7:TR?=NXXVU2FHW0GQR1XS
EW-13MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XKc2lEPTB;Mk[uNFI4PCEQvF2=MUTTRW5ITVJ?
NB13NFj4UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\zPJpKSzVyPUK2MlA6PDlizszNNVW3PWtDW0GQR1XS
NUGC-3MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rReWlEPTB;Mk[uNlExOyEQvF2=MYTTRW5ITVJ?
GMS-10MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHoTWM2OD1{Nj6yN|U{KM7:TR?=MWHTRW5ITVJ?
CHP-134MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlv6TWM2OD1{Nj6zPFY4KM7:TR?=MXPTRW5ITVJ?
SW962NILlbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTnTWM2OD1{Nj61NFIyKM7:TR?=M36zT3NCVkeHUh?=
SNU-449MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknZTWM2OD1{Nz6wPFA{KM7:TR?=NVG3dlZmW0GQR1XS
HuP-T4MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fFcmlEPTB;MkeuNFg4QSEQvF2=NY[2PY0xW0GQR1XS
SW948MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEOwbGNKSzVyPUK3MlE{PDRizszNM3;Hb3NCVkeHUh?=
NCI-H226M{DDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHvTWM2OD1{Nz60OVc5KM7:TR?=M1rpcXNCVkeHUh?=
SK-PN-DWMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTJ5Lk[wNVIh|ryPNXHjSGh5W0GQR1XS
GI-1NEP6dGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;IfZFWUUN3ME2yO{44OjFizszNNEPRTnhUSU6JRWK=
CAL-12TMmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXmTWM2OD1{OD6xNVEzKM7:TR?=NFrHfmhUSU6JRWK=
YAPCM{jjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTJ6LkK1OlQh|ryPNFSwd21USU6JRWK=
SNU-C2BMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTJ6LkK5OlQh|ryPMoDNV2FPT0WU
RCC10RGBMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7SVotKSzVyPUK4MlU1OTdizszNMoXjV2FPT0WU
ES7NYjQVld4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILqOIxKSzVyPUK5MlE1PjVizszNNFHMSWFUSU6JRWK=
PANC-03-27MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PufGlEPTB;MkmuOFQ1KM7:TR?=MlLEV2FPT0WU
ES6MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzP[I9KSzVyPUK5MlgyPTdizszNMl;mV2FPT0WU
HT-1197MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DFcGlEPTB;M{CuNFU6QCEQvF2=NYPqc5d3W0GQR1XS
ZR-75-30MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fON2lEPTB;M{CuNlM5OyEQvF2=M4XqT3NCVkeHUh?=
DBM1\2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nkd2lEPTB;M{CuOFk1OiEQvF2=NVrvXXU3W0GQR1XS
OCI-AML2NHTvd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXxXZNKSzVyPUOxMlA3QSEQvF2=MUPTRW5ITVJ?
NCI-H2170MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1e1cmlEPTB;M{GuPFUyPiEQvF2=NYXoZZZyW0GQR1XS
IST-MES1NVnHcmY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHL6OXVKSzVyPUOyMlI5QTdizszNNE\RfJpUSU6JRWK=
769-PNIe5bGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XLNGlEPTB;M{KuN|Y1OSEQvF2=MY\TRW5ITVJ?
COR-L23M2TFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTN{LkmwO|Mh|ryPM1TQZnNCVkeHUh?=
SW626NXXJXJFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PybWlEPTB;M{OuNVc4PiEQvF2=M2HtZXNCVkeHUh?=
LU-139NVzwUnh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjPeJJ2UUN3ME2zN{43PjB3IN88US=>MnK5V2FPT0WU
HT-144Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfmcFBKSzVyPUOzMlg3OyEQvF2=M1vJXHNCVkeHUh?=
CaR-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfONZVKSzVyPUOzMlk5OjJizszNM2DyS3NCVkeHUh?=
OE33MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzpTWM2OD1|ND6yPFU2KM7:TR?=MXfTRW5ITVJ?
COLO-800MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPyOZJVUUN3ME2zOE4{PjR5IN88US=>NWfmNW5JW0GQR1XS
NB14NV\BVGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPMU3B[UUN3ME2zOE41Pjh2IN88US=>NHvkWmxUSU6JRWK=
KURAMOCHIM4fl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETsR|FKSzVyPUO2MlEyQThizszNMVnTRW5ITVJ?
SW48NUL0b2dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUD2Wo5jUUN3ME2zOk4zPDd2IN88US=>M4XmSXNCVkeHUh?=
DaoyMmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHLWZJNUUN3ME2zOk43PTN6IN88US=>MV;TRW5ITVJ?
TGBC24TKBMofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXsVIwyUUN3ME2zOk43PyEQvF2=NVm0Nm5sW0GQR1XS
DU-4475MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFf0cIhKSzVyPUO2MlkxOzNizszNNV;jT4w2W0GQR1XS
SW1417MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3ZTWM2OD1|OD6wOVUzKM7:TR?=MkjKV2FPT0WU
EFO-21NFH3bIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPUdGJOUUN3ME2zPE46OzR7IN88US=>MoCxV2FPT0WU
MG-63NEHpTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXuyNJVoUUN3ME2zPU4{PDJ2IN88US=>NV3Kd5pNW0GQR1XS
LC-2-adNF;3OHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTN7LkW1NVIh|ryPMYnTRW5ITVJ?
NOMO-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;HOmlEPTB;M{muPFI4PCEQvF2=MlPxV2FPT0WU
COLO-741NYTpcHZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTRyLkGzNFQh|ryPNYLBVlJjW0GQR1XS
BxPC-3MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPMbIxKSzVyPUSwMlU3QDZizszNNFPifFNUSU6JRWK=
HSC-2NXrzUYpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\zVoNyUUN3ME20NE46OTF|IN88US=>MUXTRW5ITVJ?
UMC-11MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTRzLkK2N{DPxE1?M{fNenNCVkeHUh?=
HCC1937NH7YNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmH1TWM2OD12Mj63PFQ{KM7:TR?=MWfTRW5ITVJ?
Calu-6MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7hTIhKSzVyPUSzMlI{QDJizszNNWjGR|RUW0GQR1XS
NCI-H1573MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInFdI1KSzVyPUSzMlM1PzdizszNM3fVT3NCVkeHUh?=
SK-N-ASM4rKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvyTlhKSzVyPUSzMlYxOTlizszNNVq0Z4FUW0GQR1XS
PSN1NYrRbGdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYOxTZp[UUN3ME20OU4zPTR6IN88US=>MmnuV2FPT0WU
TE-11M1[zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUC1RmhGUUN3ME20OU41QDR{IN88US=>NGXFSYJUSU6JRWK=
NCI-H1155NVLXZlRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDneJRKSzVyPUS1Mlg6PjdizszNNEPPSZhUSU6JRWK=
KM12NUW3dFlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDoTmZEUUN3ME20OU46ODd4IN88US=>MWrTRW5ITVJ?
RO82-W-1NE[1SWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{H5ZWlEPTB;NE[uPVgzOiEQvF2=M2rDNnNCVkeHUh?=
SW1573NITxSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTR5LkO3N|Yh|ryPM{fEc3NCVkeHUh?=
CAKI-1M2Hlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfaTWM2OD12OD6yPFQ2KM7:TR?=NHXLRoVUSU6JRWK=
U-118-MGMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoP4TWM2OD12OD6zO|AzKM7:TR?=NHHEU21USU6JRWK=
KYSE-520MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\IOmlEPTB;NEiuOFAyPiEQvF2=M4nMSXNCVkeHUh?=
HT55NW[2[oJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1u5bWlEPTB;NEmuNVQ4PCEQvF2=NHPadHNUSU6JRWK=
ChaGo-K-1Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG[wUpZKSzVyPUS5MlQ4QTNizszNNXvwXG1lW0GQR1XS
IA-LMNUjCN4FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjWO3NDUUN3ME21OE43OzJ{IN88US=>MUjTRW5ITVJ?
UACC-62MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTV3LkGwOFYh|ryPNWf4N4JVW0GQR1XS
MKN7NWLsT2xPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfWO49oUUN3ME21Ok4xOjh3IN88US=>MkLyV2FPT0WU
HPAF-IIMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTV4LkSwO|Mh|ryPMnixV2FPT0WU
NTERA-S-cl-D1MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33yUGlEPTB;NUeuO|c5KM7:TR?=MWPTRW5ITVJ?
FTC-133NFKxNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTV6LkC5Olkh|ryPM2nBbnNCVkeHUh?=
MHH-ES-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTV6LkS4NVQh|ryPMnHNV2FPT0WU
JVM-2M1n1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTV6Lkm1NFYh|ryPMUDTRW5ITVJ?
TCCSUPM2TtW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DTNGlEPTB;NUmuOVI4QSEQvF2=Moj0V2FPT0WU
COLO-824M2jjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTZyLkC3NVkh|ryPM1XONXNCVkeHUh?=
647-VNInrcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfrfHdLUUN3ME22NE4yOzR5IN88US=>M1XDOXNCVkeHUh?=
HD-MY-ZNVjSfo0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTZyLkWyPVQh|ryPNVzrfZRIW0GQR1XS
LS-411NNV3NUG9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTZzLkO5NFMh|ryPNFfmcFlUSU6JRWK=
NCI-H596NET6[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHOfXFjUUN3ME22Nk44PDl4IN88US=>NHTSS4tUSU6JRWK=
C-33-ANH7peYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmWwTWM2OD14ND6wPVU4KM7:TR?=NFHZdHpUSU6JRWK=
BHYNXHpXG1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTZ2LkGyOFUh|ryPNIXQNIhUSU6JRWK=
KGNMkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHLXXRKSzVyPU[0MlU2OTRizszNNEi1NoFUSU6JRWK=
NCI-H1092MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1q3fGlEPTB;NkWuNFA6PSEQvF2=NFuybZVUSU6JRWK=
MZ1-PCNIq2eoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\DcGlEPTB;NkWuOVY1QSEQvF2=M4qwbXNCVkeHUh?=
LB831-BLCNH;YSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzYTFl6UUN3ME22OU45PDhzIN88US=>M1TSW3NCVkeHUh?=
SW620MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXJN4FKSzVyPU[2MlIxOzlizszNM4DNd3NCVkeHUh?=
HuO-3N1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTZ6LkOyN|gh|ryPM2ixV3NCVkeHUh?=
SK-HEP-1NVrQUIl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTZ7Lkm0PFYh|ryPNEPPfpNUSU6JRWK=
LCLC-103HMoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PqO2lEPTB;N{CuOlcxPSEQvF2=M4r3fnNCVkeHUh?=
KYSE-70NIXMPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvtTWM2OD15MD63PFM2KM7:TR?=NEP2Sm9USU6JRWK=
MewoNGS3[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXSyRYQ{UUN3ME23NU42ODVizszNNX7nW5VVW0GQR1XS
COLO-668M4DDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjGcGlKSzVyPUexMlg1PTFizszNMmDGV2FPT0WU
NCI-H522M1TW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTd{LkO0NVMh|ryPMn\xV2FPT0WU
NCI-H1437MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTd2LkSwOFgh|ryPM{HNXXNCVkeHUh?=
U-266NV60ZYNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTd3LkS1NVYh|ryPMlLrV2FPT0WU
MC116MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rNPGlEPTB;N{WuOVcxQCEQvF2=MVvTRW5ITVJ?
PANC-10-05M1nZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\LRWRKSzVyPUe3MlQzPDNizszNNWPSO29jW0GQR1XS
KYSE-180MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjWTWM2OD15Nz61OFU1KM7:TR?=NFz0S3RUSU6JRWK=
JARNVLCSVZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjGO5JJUUN3ME23PU4xPTR4IN88US=>MUfTRW5ITVJ?
CAL-62MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTyTWM2OD16MD6wPVUh|ryPNXixWmZZW0GQR1XS
A3-KAWMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPONldKSzVyPUiwMlIyPTRizszNNFLjU4FUSU6JRWK=
PANC-08-13MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mke3TWM2OD16MT6xO|Y5KM7:TR?=NIm1WWtUSU6JRWK=
HSC-3MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7Qb4xbUUN3ME24N{4{ODdzIN88US=>MYTTRW5ITVJ?
HTC-C3M4DW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\sSGlEPTB;OEOuOFcxOiEQvF2=M{fLVXNCVkeHUh?=
KY821NETObnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTh2LkC4PVIh|ryPNWj1WoVCW0GQR1XS
DoTc2-4510MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PKVmlEPTB;OESuNlE5PSEQvF2=NGLyZnVUSU6JRWK=
NCI-H1581M1jTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3wfGVKSzVyPUi1MlQ3PDFizszNNVL1S4l{W0GQR1XS
KARPAS-299NXXDPXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzrTWM2OD16Nj6xPVc4KM7:TR?=NE\XOnFUSU6JRWK=
IST-MEL1NWTEdpJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInNZnZKSzVyPUi2Mlg5PzJizszNM3HaTHNCVkeHUh?=
KP-N-YSMnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmruTWM2OD16OT65NFI5KM7:TR?=MYfTRW5ITVJ?
KYSE-410M2TBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XmUGlEPTB;OUGuOFA1OiEQvF2=MVPTRW5ITVJ?
TE-10MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTlzLkW2NVEh|ryPNI\zVYlUSU6JRWK=
SK-MEL-1NHLWRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrlTWM2OD17Mj65NVA3KM7:TR?=MWDTRW5ITVJ?
COLO-792MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVn3W|FHUUN3ME25OU4zPTZ2IN88US=>Mly2V2FPT0WU
SCHNV;4cYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTaXlFuUUN3ME25Ok4{QDd5IN88US=>NIqyNpNUSU6JRWK=
NCI-H1792NXniWplOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIP3V3ZKSzVyPUm2Mlg6QTJizszNMVzTRW5ITVJ?
NCI-H2029NInCbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIr6V3FKSzVyPUm2Mlk2PjZizszNMmfPV2FPT0WU
SW684NUH4bI02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXznXIZYUUN3ME25PE43PjV2IN88US=>Ml7LV2FPT0WU
NCI-H209MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTFyMD6xNlEh|ryPMkPpV2FPT0WU
HLEM1jLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHZ[WJKSzVyPUGwOU4zQDJizszNMnPHV2FPT0WU
GOTONYPJUVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfSZ3JLUUN3ME2xNFcvPzd5IN88US=>M{X2OnNCVkeHUh?=
NCI-H1793NGi2XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTFyOT6yPEDPxE1?MXTTRW5ITVJ?
D-392MGMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\hTWlEPTB;MUG3MlM6QCEQvF2=MmrBV2FPT0WU
SW1990NGGzO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnRU5dSUUN3ME2xNlAvQTVzIN88US=>MU\TRW5ITVJ?
ML-2NWizT4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjZNYRXUUN3ME2xNlEvPjd4IN88US=>NG\pXY9USU6JRWK=
NCI-H2452MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HHTWlEPTB;MUKyMlIyKM7:TR?=NIHEZ5dUSU6JRWK=
SK-MEL-30NHLnSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnFcmg{UUN3ME2xNlMvOjR2IN88US=>NG\xOnNUSU6JRWK=
SN12CNYLBcZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7Sd|RIUUN3ME2xNlQvOTd4IN88US=>NYOzfod7W0GQR1XS
NCI-H1770NXPJW2V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTF{NT61NVQh|ryPNGr4SmhUSU6JRWK=
SF268M2DOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDwO3pNUUN3ME2xNlYvOTV6IN88US=>NFvJZmlUSU6JRWK=
BALL-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nRU2lEPTB;MUK2MlI{KM7:TR?=NYn5Um5HW0GQR1XS
COLO-679NGrpNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nNW2lEPTB;MUK2Mlc2OyEQvF2=NI\tN2xUSU6JRWK=
A2780NETNZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnn0TWM2OD1zMkiuPVg5KM7:TR?=NHjoeZFUSU6JRWK=
NCI-H1651NFTMZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTvTWM2OD1zM{GuNlQ{KM7:TR?=MVvTRW5ITVJ?
NCI-H2087Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\kNGlEPTB;MUOxMlQ5OyEQvF2=MVvTRW5ITVJ?
U-87-MGMkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTRRlQ2UUN3ME2xN|MvPjB2IN88US=>MlPuV2FPT0WU
LB2518-MELM{WxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{K4NGlEPTB;MUO1Mlk6OyEQvF2=NH\i[XZUSU6JRWK=
HCT-116MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nOS2lEPTB;MUO3MlIyPyEQvF2=M{i5fHNCVkeHUh?=
Ca9-22NGP1SIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnKUmtZUUN3ME2xN|kvQDN|IN88US=>MofRV2FPT0WU
COR-L88NFLxdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTRV5NKSzVyPUG0Nk4yPCEQvF2=MVjTRW5ITVJ?
CP50-MEL-BMnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTxTWJKUUN3ME2xOFQvPTBzIN88US=>NU[4e|lHW0GQR1XS
OVCAR-8MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;kTWM2OD1zNEWuOlM3KM7:TR?=NIL6cGhUSU6JRWK=
SK-MEL-3NGXoRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoqyTWM2OD1zNEeuPFc5KM7:TR?=NXjyeFV6W0GQR1XS
GT3TKBNVey[llST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm[zTWM2OD1zNEmuPVI5KM7:TR?=NGHmVXZUSU6JRWK=
KYSE-450M1nzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPHbJRyUUN3ME2xOVEvPTN7IN88US=>NG\1cVJUSU6JRWK=
CAPAN-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXBTWM2OD1zNUOuNFY1KM7:TR?=NYXORmgxW0GQR1XS
BENMmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\pWXRKSzVyPUG1N{46OjhizszNMoXnV2FPT0WU
NCI-H1304M{\2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWny[4tFUUN3ME2xOVQvPjl2IN88US=>MmDWV2FPT0WU
KU812NHPkNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PVbGlEPTB;MUW4MlY4PCEQvF2=MX;TRW5ITVJ?
Capan-2MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTF4MD61OVMh|ryPMln3V2FPT0WU
A673MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TybGlEPTB;MU[xMlcxPSEQvF2=MWfTRW5ITVJ?
SASNVL6XYJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3e2WGlEPTB;MU[yMlY4QCEQvF2=MnrnV2FPT0WU
NYM3TUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTF4NT6zNVQh|ryPM4jTV3NCVkeHUh?=
HCE-4M1GyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTF4Nj64OFUh|ryPM2i1cHNCVkeHUh?=
MDA-MB-231M1rnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTF5Nz61NFMh|ryPMkTZV2FPT0WU
no-10Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XVXmlEPTB;MUe4MlE{PCEQvF2=MmT0V2FPT0WU
MZ7-melMlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvjU2twUUN3ME2xO|gvPDZ5IN88US=>M{nNUXNCVkeHUh?=
NCI-H82NFT2VW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;H[I5mUUN3ME2xPFAvOTZ3IN88US=>NXvJUmh5W0GQR1XS
CAL-72MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLxTWM2OD1zOEWuNFU1KM7:TR?=MWXTRW5ITVJ?
NCI-SNU-5NY[wXVA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTF6Nj64OEDPxE1?NVry[245W0GQR1XS
OVCAR-4MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7iRmZKSzVyPUG4PE4{OzNizszNM{XuS3NCVkeHUh?=
SCC-9NULDfJBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH:4WI9KSzVyPUG5NUDPxE1?NWHTTJdLW0GQR1XS
KYSE-150Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Dsb2lEPTB;MUmxMlg5QCEQvF2=MUfTRW5ITVJ?
HT-29NFzybnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3excWlEPTB;MkCxMlIyOiEQvF2=MXPTRW5ITVJ?
COLO-678NWXwWpplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTJyMT60OUDPxE1?NVfzcXNNW0GQR1XS
NCI-H650NHL4VmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzJ[G1KSzVyPUKwNk4yODNizszNMnPyV2FPT0WU
HuCCT1NFXySVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\3Tm9KSzVyPUKwOE4zODhizszNNF;vb41USU6JRWK=
SW1116MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fZdmlEPTB;MkC3MlA4PyEQvF2=MontV2FPT0WU
DBTRG-05MGNXy1ZVJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37nSWlEPTB;MkC3MlkxQSEQvF2=M4HwXXNCVkeHUh?=
SW982MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEO4bJZKSzVyPUKwO{46PDhizszNNFviZmhUSU6JRWK=
RCM-1NFTHZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTJzND63OlIh|ryPNXvx[3U4W0GQR1XS
COLO-320-HSRNEf2XWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPGTWM2OD1{MU[uNVI2KM7:TR?=NF2wOoNUSU6JRWK=
KNS-42NXTEVYg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXL0[HpDUUN3ME2yNVYvPTd2IN88US=>MnywV2FPT0WU
C2BBe1NFzQ[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnSNWFKSzVyPUKzNU46ODVizszNNWTPV5M1W0GQR1XS
CCRF-CEMMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnqxTWM2OD1{NEOuO|k2KM7:TR?=NVztZ2tHW0GQR1XS
SH-4MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHq5SFJKSzVyPUK0Ok4xQSEQvF2=MYPTRW5ITVJ?
LS-1034M4fFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTJ2Nj6yOlYh|ryPM1G5c3NCVkeHUh?=
NCI-H2347NGD3[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTWeGxtUUN3ME2yOFcvPzF|IN88US=>M4fTXHNCVkeHUh?=
RPMI-8866M{Lib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTJ2OT6yO{DPxE1?NFXqTHdUSU6JRWK=
GAKNUDROnV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rRTWlEPTB;MkWzMlAxOiEQvF2=NUPpOFF4W0GQR1XS
NB6M{XIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXkTWM2OD1{N{CuNUDPxE1?NFrjWnVUSU6JRWK=
COLO-680NMnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\Qdm9NUUN3ME2yO|IvPTJ5IN88US=>MlzKV2FPT0WU
RERF-LC-MSNU\JfId5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJ5Nj6wNFch|ryPM2PjTHNCVkeHUh?=
TGBC11TKBM{S2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHGZVZKSzVyPUK3PE4yPzhizszNMVvTRW5ITVJ?
C8166MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXVUJdpUUN3ME2yO|gvPTB4IN88US=>MoraV2FPT0WU
HDLM-2NX[5emdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX0bXpKSzVyPUK5OE41ODlizszNNX;uT4JoW0GQR1XS
IGR-1MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;lTWM2OD1{OUWuOlU6KM7:TR?=MkTMV2FPT0WU
FADUM4TxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTJ7Nz61NUDPxE1?M33He3NCVkeHUh?=
L-428Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTJ7Nz62NVYh|ryPNUS4V5pnW0GQR1XS
LU-65NYLTbpU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTNyND6zNkDPxE1?M2G1T3NCVkeHUh?=
HELNHTITWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfPTWM2OD1|MEmuPVg{KM7:TR?=MnXSV2FPT0WU
NCI-H810NFjjV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmK1TWM2OD1|MUCuOVch|ryPNYnwNVBTW0GQR1XS
C3AMlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXE[FhKSzVyPUOxNU45ODJizszNMUfTRW5ITVJ?
NCI-H630M3\1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjpOpZKSzVyPUOzNk4zQTRizszNNFfQOpZUSU6JRWK=
KP-N-YNM3XYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWq3fG5lUUN3ME2zOFEvOTJ|IN88US=>NXHwUWtuW0GQR1XS
MOLT-13M{fCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfoTWM2OD1|NEKuN|I3KM7:TR?=NYXnTXQ1W0GQR1XS
NCI-H1993NEfFc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3[y[GlEPTB;M{SyMlM3PSEQvF2=NU\GeJdkW0GQR1XS
BE-13MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVqwdXdUUUN3ME2zOFQvOTZ5IN88US=>MXzTRW5ITVJ?
IST-SL1MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\yTWM2OD1|NEeuOFAyKM7:TR?=MYDTRW5ITVJ?
TE-9Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTN4Mz61PFkh|ryPNIq4NXNUSU6JRWK=
LU-135NX\YPGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTN4Nz6wN|Uh|ryPMV\TRW5ITVJ?
T84M3m5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjvbI1KSzVyPUO3OE44OTJizszNM3e4c3NCVkeHUh?=
K-562Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7XRZpIUUN3ME2zPFMvOzZizszNM1zBXXNCVkeHUh?=
SBC-5NHnKdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIK3U2lKSzVyPUO4Ok46QDVizszNNGPJeppUSU6JRWK=
NB17NWPTRo1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LR[GlEPTB;M{myMlU6PiEQvF2=MYnTRW5ITVJ?
NCI-H2052MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTN7OD60O|Ih|ryPMmrRV2FPT0WU
HCC38NFn1Z4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjlU5VSUUN3ME20NFEvPTl|IN88US=>MoLlV2FPT0WU
NCI-H69Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTR2MT6wPFMh|ryPM1;nPHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.

Protocol(Only for Reference)

Kinase Assay: [4]

Akt kinases assay Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.

Cell Assay: [2]

Cell lines A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
Concentrations 0, 0.3, 1 and 3 μM
Incubation Time 72 or 96 hours
Method MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.

Animal Study: [2]

Animal Models SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
Formulation Formulated in 30% Captisol
Dosages 120 mg/kg
Administration Orally administered

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Yan L, AACR Annual Meeting 2009: Abstract Number: DDT01-1.

[2] Hirai H, et al. Mol Cancer Therapy, 2010, 9(7), 1956-1967.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent  ...more Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|St  ...more Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adu  ...more Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|  ...more Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

view more

Chemical Information

Download MK-2206 2HCl SDF
Molecular Weight (MW) 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 15% Captisol 17 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one

Customer Product Validation (18)


Click to enlarge
Rating
Source Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines Ser78 cells
Concentrations 5 µM
Incubation Time 1 h
Results Two selective AKT inhibitors MK-2206 and GDC-0068, both significantly reduced MKK4 phosphorylation on Ser78 in axons after injury.

Click to enlarge
Rating
Source Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck
Method analysis of luciferase activity
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results In this experiment, animalstreated with dexamethasone or MK2206 showed progressivetumor growth similar to that observed in vehicle-treated controls,while mice treated with MK2206 plus dexamethasone had significant antitumor responses.

Click to enlarge
Rating
Source Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines PC9GR4/WZR10 cells
Concentrations 1 uM
Incubation Time 72 h
Results The addition of a dual PI3K and MTOR inhibitor, PI103, or the AKT inhibitor MK-2206, did reduce the expression of pAKT neither in GR4 cells nor WZR10 cells.

Click to enlarge
Rating
Source J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck
Method 3D migration model
Cell Lines WT or Rap1b-/- neutrophil
Concentrations 2 uM
Incubation Time
Results MK-2206 treatment completely reversed elevated TEM across mouse endothelial cells of Rap1b-/- neutrophils to WT levels (A). It reduced ECM degradation of Rap1b -/- neutrophils, and inhibited their multiple protrusions (B and C). Furthermore, almost all Rap1b -/- cells treated with MK-2206 were found at the endothelial cell junctions (D).

Click to enlarge
Rating
Source Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines HUVECs
Concentrations 1 uM
Incubation Time 8 h
Results Because YAP is also a known substrate of Akt21, we examined whether blockade of the Akt pathway affects YAP phosphorylation. Both Ly294002, an inhibitor of phosphoinositide 3-kinase (PI3K), and MK-2206, an allosteric inhibitor of Akt, suppressed cell contact-mediated YAP phosphorylation.

Click to enlarge
Rating
Source Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck
Method Immunoblotting
Cell Lines CXCR4S338X-expressing BCWM.1 cells
Concentrations 0.5 uM
Incubation Time 6 h
Results As AKT and ERK, but not BTK, show continued SDF-1a-triggered activation in CXCR4S338X-expressing WM cells treated with ibrutinib, we next sought to clarify if AKT and ERK contributed to the enhanced survival of these cells. It therefore treated SDF-1acultured CXCR4S338X BCWM.1 cells with either AKT- (MK-2206 and AZD-5363) or MEK- (AS-703026, AZD-6244 and UO126) specific inhibitors with and without ibrutinib (0.5 uM) for 6 h so as to clarify the contribution of AKT and ERK to ibrutinib resistance. The inhibitory activity of MK-2206, as well as AS-703026, AZD-6244 and UO126 was confirmed by western blot analysis for pAKT (S473) and pERK (T202/Y204), respectively.

Click to enlarge
Rating
Source Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines SKNAS/SJNB8/IMR32/GIMEN/SHEP2/KCNR/NGP/LAN1/LAN5/TR14/UHGNP cell lines
Concentrations 8 μM
Incubation Time 48 h
Results The 8 μM MK-2206 treatments resulted in effective pathway inhibition in all cell lines as shown by western blot for phosphoryl ated FOXO3a and PRAS40 as well as AKT serine 473 phosphorylation.

Click to enlarge
Rating
Source Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck
Method Western blot/ Wst-1 assay
Cell Lines ATC/ FTC cell lines
Concentrations 500 nM
Incubation Time 1 h/72 h
Results One-hour treatment with the AKT inhibitor MK-2206 (0.5 μM) or with the MEK inhibitor U0126 (10 μM) effectively abolished AKT and ERK1/2 phosphorylation in all cell lines.

Click to enlarge
Rating
Source Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck
Method ELISA
Cell Lines HeLa cells
Concentrations 1 μM
Incubation Time
Results Treatment of infected cells with kinase inhibitors directed at Akt (MK-2206), MEK(PD 98059), PKC(CEC), or Pim family kinases identified a dominant role for Pim family kinases in the release of IL-8 from Salmonella-infected epithelial cells.

Click to enlarge
Rating
Source FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck
Method Clonogenic growth assay
Cell Lines U2OS cells
Concentrations 1 μM
Incubation Time 9 d
Results Specific inhibition of PKB activity using MK-2206 or triciribine also significantly reduced cell growth, although to a lesser extent compared to PI-103, suggesting that both the PKB and mTOR pathways are important for anchorage-dependent growth.

Click to enlarge
Rating
Source Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines ovarian cancer cell lines
Concentrations 1-6 μM
Incubation Time 1 h/72 h
Results Activation of pAKT by IGF-1 in the low-grade cell line HOC-7 was blocked by the AKT inhibitor MK-2206.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Confocal microscopy
Cell Lines platelets
Concentrations 1μM
Incubation Time
Results Upon treatment with increasing concentrations of AEA from 0.1 to 10 mM (Fig. B–D) platelets were fully fluorescently marked as compared to control (Fig. A) and the increase in DAF 2 fluorescence intensity appears to be dose-dependent. In agreement with data shown in Figure 4, SR1(Fig. E) and MK2206 (Fig. F) abolished fluorescence intensity induced by AEA, while LY294002 (Fig. 5G) was less potent.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines platelets
Concentrations 1 μM
Incubation Time
Results eNOSser1177 phosphorylation was greatly reduced by LY294002 and cancelled by MK2206 but it was not modified by platelet pretreatment with EGTA or BAPTA/AM.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Nitriter+Nitrate(NOX) measurement, cGMP detection
Cell Lines platelets
Concentrations 1 μM
Incubation Time 1 min
Results As shown in Figure 4 SR1 significantly reduced both NOx and cGMP formation, while SR2 failed to affect these parameters.

Click to enlarge
Rating
Source Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck
Method Western blot, clonogenic survival assay
Cell Lines U87MG cells
Concentrations 1 μM
Incubation Time 1 h
Results Akt inhibitor MK-2206 showed similar effect. MK-2206 is a potent allosteric Akt inhibitor with IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3 respectively. U87MG cells were preincubated with 1 μM MK-2206 for 1 hr, followed by irradiation at 0 - 9 Gy. As shown in Fig C, MK-2206 treatment abolished IR-induced Akt phosphorylation. Moreover, treatment with MK-2206 also increased the radiosensitivity of U87MGcells (Fig. D)

Click to enlarge
Rating
Source Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck
Method Immunofluorescence
Cell Lines HC11 cells
Concentrations 10 µM
Incubation Time 1 h
Results whole ADRP levels, estimated by Western blot , decreased only in the presence of MK -2206 and LY294002. In most cases, ADRP decorated the surface of small lipid droplets and appeared as little patches on large cytoplasmic lipid droplets. With the exception of SP600125, which induced a strong ADRP coating of almost all cytoplasmic lipid droplets (although this inhibitor did not increase ADRP synthesis), variation in the distribution of ADRP at the surface of lipid droplet was difficult to estimate, notably because the signal was faint and uneven.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results Breast cancer cells were serum starved for 24 h, pretreated with the indicated concentrations of MK-2206 for 3 h, and then treated with 100ng/ml EGF for 15 min.

Click to enlarge
Rating
Source MK-2206 2HCl purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/100 nM/250 nM/1000 nM
Incubation Time 24 h
Results The effect of MK-2206 on the serine 473 phosphorylation mark of AKT 1 was uneven and did not correlate with inhibition of AKT activity, but the AKT1 mutant cells maintained higher levels of AKT1 serine 473 phosphorylation with increasing concentrations of MK-2206. Of note, MK-2206 completely inhibited AKT2 activation at 100 nM, a concentration where PIK3CA E545K mutant, but not AKT1 mutant cells were already strongly growth inhibited. MK-2206 treatment up to 1 μM did not have strong effects on other protein biomarkers such as ribosomal protein S6, ev en though growth was suppressed by approximately 80% in MCF-7 cells at this concentration.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Akt Products

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Recently Viewed Items

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us